Syndax Pharmaceuticals定价2.5亿美元高级可转换票据

• Commercial-stage biopharmaceutical company Syndax Pharmaceuticals (SNDX) entered into privately negotiated agreements for the  issuance of $250M 2.25% convertible senior notes due 2031.
• The sale of the notes is expected to close on June 10, 2026.
• Net proceeds are expected to be ~$243M, and plans use the proceeds for general corporate purposes, including working capital, research and development, commercialization activities, and business development.
• The notes are senior unsecured obligations and will pay interest semiannually on June 15 and December 15 each year, starting December 15, 2026, at a rate of 2.25%. The notes will mature on June 15, 2031. Noteholders may convert the notes at their option before March 15, 2031.
• The stock price traded 1.4% higher on Thursday during pre-market hours of trading.

More on Syndax Pharmaceuticals

• Syndax Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation
• Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
• Syndax Pharma: Two Drug Launches Fuel Transformational Growth
• Syndax outlines 2026 operating expense target of approximately $400M as Revuforj expands in NPM1
• Syndax Pharmaceuticals GAAP EPS of -$0.48 beats by $0.13, revenue of $64.9M misses by $4.93M